Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Top Cited Papers
- 28 February 2009
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 157 (2), 352-360.e2
- https://doi.org/10.1016/j.ahj.2008.09.022
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary RiskJAMA, 2008
- Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studiesThe Lancet, 2007
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsThe New England Journal of Medicine, 2007
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialThe Lancet, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaThe New England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisThe New England Journal of Medicine, 2007
- Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol LevelsJournal of the American College of Cardiology, 2006
- Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density LipoproteinCholesterolLevelsonaBackgroundofAtorvastatinJournal of the American College of Cardiology, 2006
- Cholesteryl Ester Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemiaAtherosclerosis, 1985